Vise Technologies Inc. Raises Holdings in Biogen Inc. $BIIB

Vise Technologies Inc. grew its position in shares of Biogen Inc. (NASDAQ:BIIB) by 93.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,415 shares of the biotechnology company’s stock after purchasing an additional 2,616 shares during the quarter. Vise Technologies Inc.’s holdings in Biogen were worth $953,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in BIIB. Empowered Funds LLC grew its holdings in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of Biogen by 172.2% during the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Biogen during the second quarter worth about $216,000. Cerity Partners LLC grew its holdings in shares of Biogen by 15.3% during the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock worth $5,847,000 after purchasing an additional 6,184 shares during the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of Biogen by 13.4% during the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after purchasing an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $199.10 on Wednesday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97. The business’s 50-day moving average price is $187.94 and its 200 day moving average price is $183.85. The firm has a market cap of $29.40 billion, a P/E ratio of 21.36 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the company posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts expect that Biogen Inc. will post 14.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Royal Bank Of Canada raised their price objective on Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. Barclays began coverage on Biogen in a report on Thursday, February 19th. They set an “equal weight” rating and a $185.00 price target on the stock. UBS Group raised Biogen from a “neutral” rating to a “buy” rating and raised their price target for the stock from $185.00 to $225.00 in a report on Wednesday, April 22nd. Truist Financial lowered their price target on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a report on Monday, April 13th. Finally, HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and an average price target of $217.26.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.